WO2006100226A1 - Method for making 1-substituted 1h-imidazo[4,5-c]quinolin-4-amine compounds and intermediates therefor - Google Patents
Method for making 1-substituted 1h-imidazo[4,5-c]quinolin-4-amine compounds and intermediates therefor Download PDFInfo
- Publication number
- WO2006100226A1 WO2006100226A1 PCT/EP2006/060887 EP2006060887W WO2006100226A1 WO 2006100226 A1 WO2006100226 A1 WO 2006100226A1 EP 2006060887 W EP2006060887 W EP 2006060887W WO 2006100226 A1 WO2006100226 A1 WO 2006100226A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- carbon atoms
- group
- process according
- chain
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- MXMSULWBAQVIFP-UHFFFAOYSA-N CC[O](C)C(C)(CCOC)N Chemical compound CC[O](C)C(C)(CCOC)N MXMSULWBAQVIFP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Definitions
- the present invention concerns a method for manufacturing 1-substituted lfl-imidazo [4, 5-c] quinolin-4-amine compounds, particularly l-isobutyl-lfl-imidazo [4, 5- c] quinolin-4-amine, through their corresponding formamides .
- the invention also concerns new formamide intermediates .
- Imiquimod, l-isobutyl-lfl-imidazo [4, 5] quinolin-4-amine is an immune response modifier, useful for treating viral infections, such as genital warts.
- Imiquimod was firstly disclosed in EP 145340 and has the following structural formula:
- the present invention provides a method for manufacturing a compound of formula (I) :
- Ri is selected from the group consisting of straight-chain or branched-chain alkyl containing one to ten carbon atoms and substituted straight-chain or branched-chain alkyl containing one to ten carbon atoms, wherein the substituent is selected from the group consisting of cycloalkyl containing three to six carbon atoms and cycloalkyl containing three to six carbon atoms substituted by straight-chain or branched-chain alkyl containing one to four carbon atoms; straight-chain or branched-chain alkenyl containing two to ten carbon atoms and substituted straight-chain or branched-chain alkenyl containing two to ten carbon atoms, wherein the substituent is selected from the group consisting of cycloalkyl containing three to six carbon atoms and cycloalkyl containing three to six carbon atoms substituted by straight-chain or branched-chain alkyl containing one to four carbon atoms; hydroxyalkyl of one to be
- R a and R b are independently selected from the group consisting of hydrogen, alkyl of one to four carbon atoms, phenyl, and substituted phenyl wherein the substituent is selected from the group consisting of alkyl of one to four carbon atoms, alkoxy of one to four carbon atoms, and halogen; and Z is selected from the group consisting of alkoxy containing one to four carbon atoms, alkylamido wherein the alkyl group contains one to four carbon atoms, amino, substituted amino wherein the substituent is alkyl or hydroxyalkyl of one to four carbon atoms, azido, chloro, hydroxy, 1-morpholino, 1- pyrrolidino, and thioalkyl of one to four carbon atoms; R is selected from the group consisting of lower alkoxy, halogen, and lower alkyl; and n is zero or one, or a pharmaceutically acid addition salt thereof.
- the present invention shows important advantages over the prior art because high-pressure conditions are not required to conduct the transformation at gentle reaction temperature conditions, thus enabling to perform the process in conventional facilities. Contrary to prior art, reaction times are short and compounds (I) can be isolated almost quantitatively.
- the present invention comprises:
- R, R 1 , R 2 and n are as defined above, and X is a halogen selected from the group consisting of chlorine and bromine, with formamide, thus providing the compound of formula (III) :
- intermediates of general formula (II) wherein X is chlorine can be obtained by known methods, such as those disclosed in US 4,988,815, US 5,578,727, US 5,602,256, US 4,698,348, US 4,689,338 and US 4,929,624.
- X is bromine
- intermediates of general formula (II) can be prepared, for instance, from the corresponding N-oxides by reaction with phosphorus oxybromide.
- the 1-substituted lfl-imidazo [4, 5- c] quinoline-4-formamide (III) intermediates are prepared by reacting 4-halo-lfl-imidazo [4, 5-c] quinolines (II) with formamide in solvolytic conditions or with formamide in another solvent medium, in the presence of a base, in a wide range of temperatures, preferably from about 25 to about 150 0 C, and more preferably from about 70 to about 110 0 C.
- said solvent medium can be selected from the group of aprotic polar solvents such as dimethylsulfoxide, dimethylacetamide, N-methylpiperidone, N-methylpyrrolidone, dimethylformamide and 1, 3-dimethyl- 2-imidazolidinone, or mixtures thereof, preferably dimethylsulfoxide.
- aprotic polar solvents such as dimethylsulfoxide, dimethylacetamide, N-methylpiperidone, N-methylpyrrolidone, dimethylformamide and 1, 3-dimethyl- 2-imidazolidinone, or mixtures thereof, preferably dimethylsulfoxide.
- phase-transfer catalyst is selected from the group consisting of tetrabutylammonium bromide, tetrabutylammonium chloride and tetrabutylammonium hydrogen sulfate. Tetrabutylammonium chloride and tetrabutylammonium hydrogen sulfate are preferred.
- the bases are selected from the group consisting of alkaline or alkaline earth metal hydroxydes, alkaline or alkaline earth metal carbonates, alkaline or alkaline earth metal bicarbonates, alkaline or alkaline earth metal alkoxides or alkaline or alkaline earth metal hydrides. Alkoxides and more specifically potassium tert-butoxide are preferred.
- Intermediate formamides (III) can be isolated from the reaction medium or alternatively it is possible to force their complete conversion to corresponding final compounds (I) .
- compounds (III) When compounds (III) are isolated, then they can be hydrolyzed by known methods of Organic Chemistry. The inventors have preferred not to isolate said intermediates in order to simplify the process.
- intermediate formamides (III) are not isolated.
- the present invention comprises the compounds of formula (III) .
- the present invention comprises the compound of formula (III) which is 1- isobutyl-1-ff-imidazo [4, 5-c] quinoline-4-formamide .
- the method of the present invention does not require special manufacturing facilities because high pressure is not required and operation temperatures are gentle. Moreover, when the intermediate formamides are not isolated, the final corresponding products are afforded in a unique step with an almost quantitative yield.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
Abstract
Description
Claims
Priority Applications (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BRPI0609399-0A BRPI0609399A2 (en) | 2005-03-21 | 2006-03-20 | method for producing 1-substituted 1h-imidazo [4,5-c] quinolin-4-amine compounds and intermediates thereof |
| CA2601542A CA2601542C (en) | 2005-03-21 | 2006-03-20 | Method for making 1-substituted 1h-imidazo[4,5-c]quinolin-4-amine compounds and intermediates therefor |
| MX2007011238A MX2007011238A (en) | 2005-03-21 | 2006-03-20 | Method for making 1-substituted 1h-imidazo[4,5-c]quinolin-4-amine compounds and intermediates therefor. |
| AT06708801T ATE469901T1 (en) | 2005-03-21 | 2006-03-20 | METHOD FOR PRODUCING 1-SUBSTITUTED 1H-IMIDAZOÄ4,5-CUCHINOLIN-4-AMINE COMPOUNDS AND INTERMEDIATE PRODUCTS THEREFOR |
| SI200630750T SI1879893T1 (en) | 2005-03-21 | 2006-03-20 | METHOD FOR MAKING 1-SUBSTITUTED 1H-IMIDAZO?á4,5-C?åQUINOLIN-4-AMINE COMPOUNDS AND INTERMEDIATES THEREFOR |
| JP2008502393A JP2008533189A (en) | 2005-03-21 | 2006-03-20 | Process for preparing 1-substituted 1H-imidazo [4,5-c] quinolin-4-amine compounds and intermediates therefor |
| EP06708801A EP1879893B1 (en) | 2005-03-21 | 2006-03-20 | Method for making 1-substituted 1h-imidazo[4,5-c]quinolin-4-amine compounds and intermediates therefor |
| US11/886,726 US8106202B2 (en) | 2005-03-21 | 2006-03-20 | Method for making 1-substituted 1H-imidazo [4,5-C] quinolin-4-amine compounds and intermediates therefor |
| DE602006014677T DE602006014677D1 (en) | 2005-03-21 | 2006-03-20 | PROCESS FOR PREPARING 1-SUBSTITUTED 1H-IMIDAZOE4,5-CUCHINOLINE-4-AMINE COMPOUNDS AND INTERMEDIATES THEREFOR |
| PL06708801T PL1879893T3 (en) | 2005-03-21 | 2006-03-20 | Method for making 1-substituted 1h-imidazo[4,5-c]quinolin-4-amine compounds and intermediates therefor |
| AU2006226412A AU2006226412A1 (en) | 2005-03-21 | 2006-03-20 | Method for making 1-substituted 1H-imidazo(4,5-c)quinolin-4-amine compounds and intermediates therefor |
| DK06708801.3T DK1879893T3 (en) | 2005-03-21 | 2006-03-20 | Process for the Preparation of 1-Substituted 1H-Imidazo [4,5-c] Quinoline-4-Amine Compounds and Intermediates |
| IL186040A IL186040A (en) | 2005-03-21 | 2007-09-18 | Method for making 1-substituted 1h-imidazo[4,5-c]quinolin-4-amine compounds and intermediates therefor |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05102229 | 2005-03-21 | ||
| EP05102229.1 | 2005-03-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2006100226A1 true WO2006100226A1 (en) | 2006-09-28 |
Family
ID=36591271
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP2006/060887 Ceased WO2006100226A1 (en) | 2005-03-21 | 2006-03-20 | Method for making 1-substituted 1h-imidazo[4,5-c]quinolin-4-amine compounds and intermediates therefor |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US8106202B2 (en) |
| EP (1) | EP1879893B1 (en) |
| JP (1) | JP2008533189A (en) |
| KR (1) | KR20070113309A (en) |
| CN (1) | CN101146810A (en) |
| AT (1) | ATE469901T1 (en) |
| AU (1) | AU2006226412A1 (en) |
| BR (1) | BRPI0609399A2 (en) |
| CA (1) | CA2601542C (en) |
| CY (1) | CY1111227T1 (en) |
| DE (1) | DE602006014677D1 (en) |
| DK (1) | DK1879893T3 (en) |
| ES (1) | ES2346687T3 (en) |
| IL (1) | IL186040A (en) |
| MX (1) | MX2007011238A (en) |
| PL (1) | PL1879893T3 (en) |
| PT (1) | PT1879893E (en) |
| RU (1) | RU2007139008A (en) |
| SI (1) | SI1879893T1 (en) |
| WO (1) | WO2006100226A1 (en) |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008090550A3 (en) * | 2007-01-24 | 2008-12-11 | Chemagis Ltd | Imiquimod production process |
| US7659398B2 (en) | 2007-02-14 | 2010-02-09 | Chemagis Ltd. | Imiquimod production process |
| US8357374B2 (en) | 2007-02-07 | 2013-01-22 | The Regents Of The University Of California | Conjugates of synthetic TLR agonists and uses therefor |
| US8729088B2 (en) | 2009-02-11 | 2014-05-20 | The Regents Of The University Of California | Toll-like receptor modulators and treatment of diseases |
| US8846697B2 (en) | 2006-05-31 | 2014-09-30 | The Regents Of The University Of California | Purine analogs |
| US9066940B2 (en) | 2009-02-06 | 2015-06-30 | Telormedix, Sa | Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration |
| US9359360B2 (en) | 2005-08-22 | 2016-06-07 | The Regents Of The University Of California | TLR agonists |
| US10975075B2 (en) | 2015-04-02 | 2021-04-13 | Merck Patent Gmbh | Imidazolonylquinolines and the use thereof as ATM kinase inhibitors |
| EP3950687A1 (en) | 2020-08-07 | 2022-02-09 | PHV Pharma | Industrial method for synthesising imiquimod from quinoline-2,4-diol applicable to the pharmaceutical use thereof |
| US11697851B2 (en) | 2016-05-24 | 2023-07-11 | The Regents Of The University Of California | Early ovarian cancer detection diagnostic test based on mRNA isoforms |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2974153A1 (en) | 2015-02-03 | 2016-08-11 | Trillium Therapeutics Inc. | Fluorinated imidazo[4,5-c]quinoline derivatives as inhibitors of bromodomain containing proteins |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4689338A (en) * | 1983-11-18 | 1987-08-25 | Riker Laboratories, Inc. | 1H-Imidazo[4,5-c]quinolin-4-amines and antiviral use |
| US5741908A (en) * | 1996-06-21 | 1998-04-21 | Minnesota Mining And Manufacturing Company | Process for reparing imidazoquinolinamines |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7323568B2 (en) * | 2005-12-12 | 2008-01-29 | Chemagis Ltd. | Process for preparing Imiquimod |
-
2006
- 2006-03-20 CA CA2601542A patent/CA2601542C/en not_active Expired - Lifetime
- 2006-03-20 RU RU2007139008/04A patent/RU2007139008A/en not_active Application Discontinuation
- 2006-03-20 AU AU2006226412A patent/AU2006226412A1/en not_active Abandoned
- 2006-03-20 DK DK06708801.3T patent/DK1879893T3/en active
- 2006-03-20 SI SI200630750T patent/SI1879893T1/en unknown
- 2006-03-20 US US11/886,726 patent/US8106202B2/en active Active
- 2006-03-20 BR BRPI0609399-0A patent/BRPI0609399A2/en not_active Application Discontinuation
- 2006-03-20 AT AT06708801T patent/ATE469901T1/en active
- 2006-03-20 PL PL06708801T patent/PL1879893T3/en unknown
- 2006-03-20 CN CNA2006800092878A patent/CN101146810A/en active Pending
- 2006-03-20 WO PCT/EP2006/060887 patent/WO2006100226A1/en not_active Ceased
- 2006-03-20 MX MX2007011238A patent/MX2007011238A/en not_active Application Discontinuation
- 2006-03-20 DE DE602006014677T patent/DE602006014677D1/en not_active Expired - Lifetime
- 2006-03-20 JP JP2008502393A patent/JP2008533189A/en active Pending
- 2006-03-20 PT PT06708801T patent/PT1879893E/en unknown
- 2006-03-20 EP EP06708801A patent/EP1879893B1/en not_active Expired - Lifetime
- 2006-03-20 ES ES06708801T patent/ES2346687T3/en not_active Expired - Lifetime
- 2006-03-20 KR KR1020077024147A patent/KR20070113309A/en not_active Withdrawn
-
2007
- 2007-09-18 IL IL186040A patent/IL186040A/en active IP Right Grant
-
2010
- 2010-09-01 CY CY20101100801T patent/CY1111227T1/en unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4689338A (en) * | 1983-11-18 | 1987-08-25 | Riker Laboratories, Inc. | 1H-Imidazo[4,5-c]quinolin-4-amines and antiviral use |
| US5741908A (en) * | 1996-06-21 | 1998-04-21 | Minnesota Mining And Manufacturing Company | Process for reparing imidazoquinolinamines |
Non-Patent Citations (2)
| Title |
|---|
| IZUMI T ET AL: "1H-Imidazo[4,5-c]quinoline derivatives as novel potent TNF-alpha suppressors: Synthesis and structure-activity relationship of 1-,2-and 4-substituted 1-H-imidazo[4,5-c]quinolines or 1H-imidazo[4,5-c]pyridines", BIOORGANIC & MEDICINAL CHEMISTRY, vol. 11, 2003, pages 2541 - 2550, XP002387324 * |
| VERCEK B ET AL: "Neighboring Group Interaction in Ortho-Substituted Heterocycles. 2. 1,2,4-Oxadiazolylpyridines and Pyrido[2,3-d]pyrimidine 3-Oxides", JOURNAL OF ORGANIC CHEMISTRY, AMERICAN CHEMICAL SOCIETY. EASTON, US, vol. 44, no. 10, 1979, pages 1695 - 1699, XP002360944, ISSN: 0022-3263 * |
Cited By (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9359360B2 (en) | 2005-08-22 | 2016-06-07 | The Regents Of The University Of California | TLR agonists |
| US8846697B2 (en) | 2006-05-31 | 2014-09-30 | The Regents Of The University Of California | Purine analogs |
| US7943771B2 (en) | 2007-01-24 | 2011-05-17 | Chemagis Ltd. | Imiquimod production process |
| WO2008090550A3 (en) * | 2007-01-24 | 2008-12-11 | Chemagis Ltd | Imiquimod production process |
| US8357374B2 (en) | 2007-02-07 | 2013-01-22 | The Regents Of The University Of California | Conjugates of synthetic TLR agonists and uses therefor |
| US8790655B2 (en) | 2007-02-07 | 2014-07-29 | The Regents Of The University Of California | Conjugates of synthetic TLR agonists and uses therefor |
| US9050376B2 (en) | 2007-02-07 | 2015-06-09 | The Regents Of The University Of California | Conjugates of synthetic TLR agonists and uses therefor |
| US7659398B2 (en) | 2007-02-14 | 2010-02-09 | Chemagis Ltd. | Imiquimod production process |
| US9066940B2 (en) | 2009-02-06 | 2015-06-30 | Telormedix, Sa | Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration |
| US9107919B2 (en) | 2009-02-06 | 2015-08-18 | Telormedix Sa | Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration |
| US8729088B2 (en) | 2009-02-11 | 2014-05-20 | The Regents Of The University Of California | Toll-like receptor modulators and treatment of diseases |
| US10975075B2 (en) | 2015-04-02 | 2021-04-13 | Merck Patent Gmbh | Imidazolonylquinolines and the use thereof as ATM kinase inhibitors |
| US11608338B2 (en) | 2015-04-02 | 2023-03-21 | Merck Patent Gmbh | Imidazolonylquinolines and the use thereof as ATM kinase inhibitors |
| US11697851B2 (en) | 2016-05-24 | 2023-07-11 | The Regents Of The University Of California | Early ovarian cancer detection diagnostic test based on mRNA isoforms |
| EP3950687A1 (en) | 2020-08-07 | 2022-02-09 | PHV Pharma | Industrial method for synthesising imiquimod from quinoline-2,4-diol applicable to the pharmaceutical use thereof |
| FR3113287A1 (en) | 2020-08-07 | 2022-02-11 | Phv Pharma | Industrial process for the synthesis of imiquimod from quinoline-2,4-diol applicable to its pharmaceutical use |
Also Published As
| Publication number | Publication date |
|---|---|
| ATE469901T1 (en) | 2010-06-15 |
| IL186040A (en) | 2011-11-30 |
| SI1879893T1 (en) | 2010-09-30 |
| RU2007139008A (en) | 2009-04-27 |
| JP2008533189A (en) | 2008-08-21 |
| BRPI0609399A2 (en) | 2010-03-30 |
| CN101146810A (en) | 2008-03-19 |
| EP1879893B1 (en) | 2010-06-02 |
| DK1879893T3 (en) | 2010-09-13 |
| AU2006226412A1 (en) | 2006-09-28 |
| IL186040A0 (en) | 2008-02-09 |
| DE602006014677D1 (en) | 2010-07-15 |
| US20090005566A1 (en) | 2009-01-01 |
| KR20070113309A (en) | 2007-11-28 |
| CA2601542C (en) | 2012-09-18 |
| PL1879893T3 (en) | 2010-11-30 |
| CA2601542A1 (en) | 2006-09-28 |
| PT1879893E (en) | 2010-09-02 |
| ES2346687T3 (en) | 2010-10-19 |
| CY1111227T1 (en) | 2015-06-11 |
| EP1879893A1 (en) | 2008-01-23 |
| US8106202B2 (en) | 2012-01-31 |
| MX2007011238A (en) | 2007-10-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL186040A (en) | Method for making 1-substituted 1h-imidazo[4,5-c]quinolin-4-amine compounds and intermediates therefor | |
| US11040953B2 (en) | Process for the preparation of a diarylthiohydantoin compound | |
| WO2004009593A1 (en) | Preparation of 1h-imidazo[4,5-c]quinolin-4-amines via1h-imidazo [4,5-c]quinolin-4-phthalimide intermediates | |
| CZ291368B6 (en) | Process and intermediates for preparing 1-substituted-1H-imidazo[4,5-c]quinolin-4-amine | |
| US20070100146A1 (en) | Process for the preparation of imidazo[4,5-c]-quinolin-4-amines | |
| US6653477B2 (en) | Imidazopyridin-8-ones | |
| HK1116493A (en) | Method for making 1-substituted 1h-imidazo[4,5-c]quinolin-4-amine compounds and intermediates therefor | |
| WO2006070408A2 (en) | A process for the preparation of substantially pure 4-amino-1-isobutyl-1h-imidazo[4,5-c]-quinoline (imiquimod) | |
| HK1231871A1 (en) | A process for the preparation of compound and synthetic intermediates thereof | |
| HK1167136B (en) | A process for the preparation of 6-(7-((1-aminocyclopropyl)methoxy)-6-methoxyquinolin-4-yloxy)-n-methyl-1-naphthamide and synthetic intermediates thereof | |
| HK1167136A1 (en) | A process for the preparation of 6-(7-((1-aminocyclopropyl)methoxy)-6-methoxyquinolin-4-yloxy)-n-methyl-1-naphthamide and synthetic intermediates thereof | |
| JP2014227362A (en) | Method for producing antibacterial compound | |
| KR20070102652A (en) | Method for preparing 4-amino-1-isobutyl-1Η-imidazo [4,5-c] -quinoline (imiquimod) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 2601542 Country of ref document: CA |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2006226412 Country of ref document: AU |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 3405/KOLNP/2007 Country of ref document: IN |
|
| WWE | Wipo information: entry into national phase |
Ref document number: MX/a/2007/011238 Country of ref document: MX |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 186040 Country of ref document: IL |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2008502393 Country of ref document: JP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 12007502070 Country of ref document: PH Ref document number: 200680009287.8 Country of ref document: CN |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| ENP | Entry into the national phase |
Ref document number: 2006226412 Country of ref document: AU Date of ref document: 20060320 Kind code of ref document: A |
|
| WWP | Wipo information: published in national office |
Ref document number: 2006226412 Country of ref document: AU |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2006708801 Country of ref document: EP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 1020077024147 Country of ref document: KR |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2007139008 Country of ref document: RU |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 11886726 Country of ref document: US |
|
| WWP | Wipo information: published in national office |
Ref document number: 2006708801 Country of ref document: EP |
|
| ENP | Entry into the national phase |
Ref document number: PI0609399 Country of ref document: BR Kind code of ref document: A2 |










